RIPK1 and triple-negative breast carcinoma: Biomarkers identifying which tumor types are likely to show success with Smac mimetics are limited although a recent publication suggests in triple negative breast cancer tumors, high mRNA expression of TNF, RIPK1 and STX37 are indicative of response [42].